Recent oncology updates reveal a dynamic landscape of drug development and clinical trial advances. Highlights include AbbVie and Genmab’s Phase 3 success for the T cell engager Epkinly in follicular lymphoma, Dana-Farber Cancer Institute’s novel blood test SWIFT-seq for multiple myeloma detection, Jazz Pharmaceuticals’ dordaviprone achieving FDA accelerated approval for diffuse midline glioma, and Chimerix’s brain cancer drug’s regulatory milestones. Additionally, research highlights include new NSD2 histone methyltransferase inhibitors and discovery of novel biomarkers for diverse cancers, reflecting ongoing commitment to precision medicine in oncology.